Prevention or treatment of chronic organ injury

Patent metadata

Field	Value
Publication number	US-12440479-B2
Application number	US-201917042027-A
Country	US
Kind code	B2
Filing date	Mar 27, 2019
Priority date	Mar 28, 2018
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

The present disclosure is directed to novel therapeutic approaches for the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of an organ. Specifically disclosed are agents for use in increasing homodimer-formation of ARNT in an organ in the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of said organ, as further defined in the claims. In embodiments, said agent may be (i) an inhibitor of protein phosphatase 2A (PP2A) activity, (ii) an inhibitor of the transcriptional repressor complex FKBP12/YY1, or (iii) an expression construct, which is capable of over-expressing ARNT in said organ, as well as combinations of (i), (ii), and/or (iii).

First claim

The invention claimed is:

1. A method for the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of an organ of a subject in need thereof, comprising the step of administering an agent to said subject to increase homodimer-formation of ARNT in said organ.

2. The method of claim 1 , wherein the increased homodimer-formation of ARNT is to increase the expression of ALK3.

3. The method of claim 1 , wherein the increased homodimer-formation of ARNT is by an increased expression of ARNT.

4. The method of claim 1 , wherein the increased homo-dimer formation of ARNT is to protect said organ against chronic injury, progressive loss of functional parenchymal cells, or fibrosis.

5. The method of claim 1 , wherein said chronic injury, progressive loss of functional parenchymal cells, or fibrosis is caused by a chronic progressive disease, or by a long-term exposure to a substance which is toxic for said organ, or by a long-term ischemia.

6. The method of claim 1 , wherein the organ is selected from the group consisting of kidney, heart, intestine, spleen, lung, liver, brain, spinal cord, skin, and pancreas.

7. The method of claim 1 wherein said method is:
(i) for the prevention, treatment and/or for delaying progression of a condition selected from the group consisting of chronic kidney disease; or
(ii) for the prevention of and/or for delaying progression to end-stage renal disease; or
(iii) for the prevention, treatment, and/or for delaying progression of pulmonary fibrosis; or
(iv) for the prevention, treatment, and/or for delaying progression of a fibrosis selected from the group consisting of cystic fibrosis, idiopathic pulmonary fibrosis, progressive massive fibrosis, liver cirrhosis, artrial fibrosis of the heart, endomyocardial fibrosis, glial scar of the brain, keloid of the skin, and Crohn's disease of the intestine; or
(v) for the prevention, treatment, and/or for delaying progression of chronic cardiac injury; or
(vi) for protecting from impairment of organ function or histopathological patterns of chronified injury, applied before, during, or after injury; or
(vii) for the treatment or prevention of diabetes mellitus.

8. The method of claim 1 , wherein said agent is an inhibitor of protein phosphatase 2A (PP2A) activity.

9. The method of claim 8 , wherein said inhibitor is:
(a) a siRNA, or
(b) a vivo morpholino, or (c) a small molecule selected from the group consisting of (i) an oxabicycloheptane or oxabicycloheptene, (ii) okadaic acid, (iii) fostriecin, and (iv) calyculin A.

10. The method of claim 1 , wherein said agent is an inhibitor of the transcriptional repressor complex FKBP12/YY1.

11. The method of claim 10 , wherein said agent is an inhibitor of FKBP12 or an inhibitor of YY1.

12. The method of claim 10 , wherein said agent is an inhibitor of FKBP12 selected from the group consisting of a small molecule, a siRNA, and a vivo morpholino.

13. The method of claim 12 , wherein said inhibitor of FKBP12 is:
(a) a small molecule selected from the group consisting of (i) a pipecolic acid derivative, (ii) rapamycin, FK 506 and derivatives thereof; or
(b) a vivo morpholino comprising the sequence shown in SEQ ID NO: 9.

14. The method of claim 10 , wherein said agent is an inhibitor of YY1 selected from the group consisting of a vivo morpholino and a siRNA.

15. The method of claim 14 , wherein said inhibitor of YY1 is a vivo morpholino comprising the sequence shown in SEQ ID NO: 10.

16. The method of claim 1 , wherein said agent is an expression construct, which is capable of over-expressing ARNT in said organ.

17. The method of claim 16 , wherein said expression of ARNT is under the control of a constitutive promoter, an inducible promoter, or a promoter which selectively expresses ARNT in said organ.

18. The method of claim 1 , wherein the agent is a combination of at least two of (i) an inhibitor of protein phosphatase 2A (PP2A) activity, (ii) an inhibitor of the transcriptional repressor complex FKBP12/YY1, and (iii) an expression construct, which is capable of over-expressing ARNT in said organ.

19. The method of claim 1 , wherein the agent is a combination of (i) an inhibitor of protein phosphatase 2A (PP2A) activity, and (ii) an inhibitor of the transcriptional repressor complex FKBP12/YY1.

20. The method of claim 19 , wherein the agent is a combination of (i) GPI 1046; (ii) FK-506 or a derivative thereof; and (iii) LB100.

21. The method of claim 9 , wherein the oxabicycloheptane or oxabicycloheptene is LB-100, LB-102 or LB-107.

22. The method of claim 13 , wherein the pipecolic acid derivative is GPI 1046, GPI 1044, GPI 1102, GPI 1116, or GPI 1206.

23. The method of claim 13 , wherein the vivo morpholino consists of the sequence shown in SEQ ID NO: 9.

24. The method of claim 15 , wherein the vivo morpholino consists of the sequence shown in SEQ ID NO: 10.

Assignees

• Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin
• Univ Texas

Inventors

• Zeisberg Michael
• Zeisberg Elisabeth
• Tampe Björn
• Tampe Désiree
• Mueller Gerhard Anton
• Kalluri Raghu

Classifications

• A61P13/12

  of the kidneys · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61K31/7125

  Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters · CPC title